Sorafenib inhibits multiple pathways involved in tumor growth and angiogenesis, such as vascular endothelial growth factor receptor 2/3 (VEGFR 2/3) and platelet-derived growth factor receptor (PDGFR), and has been linked to cardiotoxicity, mainly arterial hypertension and atrial fibrillation (AF). This evidence concerns the gene PDGFRB and atrial fibrillation.